Edwards Lifesciences Corporation (ETR:EWL)

Market Cap	36.03B
Revenue (ttm)	5.25B
Net Income (ttm)	4.03B
Shares Out	n/a
EPS (ttm)	6.73
PE Ratio	8.94
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	512
Open	61.20
Previous Close	61.33
Day's Range	61.20 - 61.20
52-Week Range	54.00 - 87.12
Beta	n/a
RSI	41.09
Earnings Date	Apr 23, 2025

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EWL

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Financial numbers in USD